Literature DB >> 16187070

Expression and localization of versican during postnatal development of rat temporomandibular joint disc.

Naoko Toriya1, Taishin Takuma, Toshiya Arakawa, Yoshihiro Abiko, Yasuyuki Sasano, Ichiro Takahashi, Yasunori Sakakura, Firoz Rahemtulla, Itaru Mizoguchi.   

Abstract

To analyze the growth-related changes in extracellular matrix components in temporomandibular joint (TMJ) discs, the expression and localization of the core protein of a large chondroitin sulphate proteoglycan, versican, in rat TMJ discs during postnatal development (2-32 weeks) were examined using Western blot analysis, real-time quantitative PCR and immunohistochemistry. Western blot analysis showed that rat TMJ discs predominantly expressed one isoform (V1) and the core protein sharply increased after birth, reached a peak at 8 weeks, and then gradually decreased up to 32 weeks. Real-time quantitative PCR with TaqMan probes indicated that mRNA expression of versican was highest at 2 weeks and gradually decreased with growth. An immunohistochemical study showed that staining for versican was weak and evenly distributed in TMJ discs at 2 weeks. Regional differences in staining for versican became prominent after 8 weeks; staining was intense in the anterior and posterior peripheral attachments, and weak in the central part of the discs. These results demonstrate that growth-related changes and regional differences exist in the expression of versican in the TMJ discs of growing rats, and these probably reflect the changes in the biomechanical environment caused by the development of orofacial functions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187070     DOI: 10.1007/s00418-005-0020-1

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  43 in total

1.  Cytokine mRNA quantification by real-time PCR.

Authors:  Patrick Stordeur; Lionel F Poulin; Ligia Craciun; Ling Zhou; Liliane Schandené; Aurore de Lavareille; Stanislas Goriely; Michel Goldman
Journal:  J Immunol Methods       Date:  2002-01-01       Impact factor: 2.303

2.  Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4.

Authors:  J D Sandy; J Westling; R D Kenagy; M L Iruela-Arispe; C Verscharen; J C Rodriguez-Mazaneque; D R Zimmermann; J M Lemire; J W Fischer; T N Wight; A W Clowes
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

3.  The sensitivity of versican from rabbit lung to gelatinase A (MMP-2) and B (MMP-9) and its involvement in the development of hydraulic lung edema.

Authors:  A Passi; D Negrini; R Albertini; G Miserocchi; G De Luca
Journal:  FEBS Lett       Date:  1999-07-30       Impact factor: 4.124

4.  A biochemical analysis of human periodontal tissue proteoglycans.

Authors:  H Larjava; L Häkkinen; F Rahemtulla
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

5.  Effects of intraoral splint wear on proteoglycans in the temporomandibular joint disc.

Authors:  B J Sindelar; S P Evanko; T Alonzo; S W Herring; T Wight
Journal:  Arch Biochem Biophys       Date:  2000-07-01       Impact factor: 4.013

Review 6.  Versican: a versatile extracellular matrix proteoglycan in cell biology.

Authors:  Thomas N Wight
Journal:  Curr Opin Cell Biol       Date:  2002-10       Impact factor: 8.382

7.  Immunohistochemical localization of proteoglycans in human periodontium.

Authors:  L Häkkinen; O Oksala; T Salo; F Rahemtulla; H Larjava
Journal:  J Histochem Cytochem       Date:  1993-11       Impact factor: 2.479

8.  Human abdominal aortic aneurysm is characterized by decreased versican concentration and specific downregulation of versican isoform V(0).

Authors:  A D Theocharis; I Tsolakis; A Hjerpe; N K Karamanos
Journal:  Atherosclerosis       Date:  2001-02-01       Impact factor: 5.162

9.  Cloning and primary structure of neurocan, a developmentally regulated, aggregating chondroitin sulfate proteoglycan of brain.

Authors:  U Rauch; L Karthikeyan; P Maurel; R U Margolis; R K Margolis
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

10.  Small proteoglycans from different regions of the fibrocartilaginous temporomandibular joint disc.

Authors:  P G Scott; T Nakano; C M Dodd
Journal:  Biochim Biophys Acta       Date:  1995-05-11
View more
  7 in total

Review 1.  The histochemistry and cell biology vade mecum: a review of 2005-2006.

Authors:  Douglas J Taatjes; Christian Zuber; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2006-11-24       Impact factor: 4.304

Review 2.  Recent progress in histochemistry.

Authors:  Christian Zuber; Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2007-10-31       Impact factor: 4.304

3.  Phenotypes of articular disc cells in the rat temporomandibular joint as demonstrated by immunohistochemistry for nestin and GFAP.

Authors:  Hitoshi Miyako; Akiko Suzuki; Kayoko Nozawa-Inoue; Jin Magara; Yoshiro Kawano; Kazuhiro Ono; Takeyasu Maeda
Journal:  J Anat       Date:  2011-06-16       Impact factor: 2.610

4.  Topographical variation in the distributions of versican, aggrecan and perlecan in the foetal human spine reflects their diverse functional roles in spinal development.

Authors:  Susan M Smith; John M Whitelock; Renato V Iozzo; Christopher B Little; James Melrose
Journal:  Histochem Cell Biol       Date:  2009-08-11       Impact factor: 4.304

Review 5.  TMJ disorders: future innovations in diagnostics and therapeutics.

Authors:  Sunil Wadhwa; Sunil Kapila
Journal:  J Dent Educ       Date:  2008-08       Impact factor: 2.264

6.  Aggrecan, versican and type VI collagen are components of annular translamellar crossbridges in the intervertebral disc.

Authors:  James Melrose; Susan M Smith; Richard C Appleyard; Christopher B Little
Journal:  Eur Spine J       Date:  2007-10-31       Impact factor: 3.134

Review 7.  Part I: Development and Physiology of the Temporomandibular Joint.

Authors:  David L Stocum; W Eugene Roberts
Journal:  Curr Osteoporos Rep       Date:  2018-08       Impact factor: 5.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.